respiratory syncyti virus rev import caps tract disease infant elderly current license vaccine avail describe develop safe effect entrants subunit base recombin fusion f protein bound surface immunostimulatori bacteriumlik partial blp derive foodgrad bacterium lactococcu last differ variant analyze respect conform reactive neutral antibody assume protein mimic meast press form expo extent elev editor repertoire correspond posts structure result india soluble ectodomain readily adopt genre prevent termini admit primer motif whose format mutant two during cleavage site put recon well monoclonal antibody palivizumab much le potent prefusionspecif increase highest observe feature combine vaccine mouse cotton rat load latter prefusionlik blp result potent induce specify immunoglobulin significantly decrease tier lung upon challenge more contrast anim vaccine formalininactiv receive exhibit high level secretary iga nose rsvneutral serum show symptom enhance 